Stemokin / NeogenСтемокин / Неоген
A synthetic three-amino-acid peptide (Ile–Glu–Trp), also called Neogen, studied in blood-cell and immune research.
What the studies found
Comparison in people · 2015
Stemokin in treatment and prevention of pyoderma in military personnel
- Reported clinical recovery in the adjunct-treatment arm
- 74.36% among 39 treated participants
- Reported pyoderma incidence in the prevention arm
- 17.5% among 40 participants over follow-up up to 12 months
The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.
Study notes · methods, sources and limitations
Participants or model Treatment comparison: 39 adjunctive Stemokin versus 37 basic care; prevention comparison: 40 versus 36. Participant overlap unresolved.
Important limitations
- Independent replication and full risk-of-bias appraisal remain unresolved. No personalized treatment or safety conclusion follows from this record.
- These arm-level proportions are not causal effect estimates. The excerpt gives no percentages for the comparison group. Allocation, blinding and overlap between the treatment and prevention groups remain unresolved; the reports may count some participants more than once.
Conference abstract on Dermatology in Russia, posted 25 January 2015; underlying study dates unresolved · Conference abstract
Animal research · 2016
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Study of multiple preparations
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
Study notes · methods, sources and limitations
Participants or model Intact mice, donor marrow and irradiated recipient-mouse colony assays
Important limitations
- AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported. Related publications may share experiments; source count is not independent-study count.
ChemMedChem · Publication record
Animal research · 2005
Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.
Study of multiple preparations
Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.
Study notes · methods, sources and limitations
Participants or model Mice; splenic colony-forming, CD34-positive-cell and T-cell assays
Important limitations
- Mechanistic interpretation does not establish CD34 as a directly bound receptor. Related-isomer experiments do not prove clinical effects of either marketed preparation. Colony formation is not proof of long-term self-renewing stem-cell expansion.
Bulletin of Experimental Biology and Medicine. 140(3):348–351 · Indexed abstract
About Stemokin / Neogen
Names in this research collection
Neogen · IEW
Research background
Synthetic Ile–Glu–Trp tripeptide (IEW), studied in hematopoietic experiments and Russian clinical immune research. It is distinct from whole tissue extracts.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
Conference sources and research collaborators ↗
- Compound class
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Comparative clinical report; methods and overlap unresolved
Study methods
Source-specific designs and limitations below
Independent replication
Related reports are not automatically independent evidence
Source access
Linked publications; access and review scope shown per record
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2000
Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis — US6159940A
Some animal survival and immune-cell observations were favorable, without an established human treatment result.
Tumor-model survival descriptions · Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experiment · Different experimental conditions; not patient survival
Study notes and original source
Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis — US6159940A
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Vladislav I. Deigin, Andrei M. Korotkov · US6159940A · patent family 26653668
Some animal survival and immune-cell observations were favorable, without an established human treatment result.
Results and tables
Reported patent results
Reported findings
Some animal survival and immune-cell observations were favorable, without an established human treatment result.
Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.
Population or model Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Tumor-model survival descriptions | Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experiment | Different experimental conditions; not patient survival |
| Longer combination observation | An approximately 20-day survival extension and survivors at 60 days described for another combination | The effect reflects the combination. The contribution of Ile-Glu-Trp alone is unclear. |
| Animal observations | No deaths reported during the described 30-day toxicity observation; selected thymus/spleen cell counts increased | These observations do not establish a human safety margin · 30 days |
Different animal protocols and combinations cannot be pooled. No reliable human immune-restoration or cancer-treatment effect is established by this disclosure.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The family contains multiple sequences; a peptide use claim is not proof of broad clinical immune restoration.
- Different animal protocols and combinations cannot be pooled. No reliable human immune-restoration or cancer-treatment effect is established by this disclosure.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · 2005
Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.
Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.
Study notes and original source
Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.
Related L- and D-iEW isomers; preparation equivalence is not inferred
Format: Journal article · Reviewed: Indexed abstract reviewed
O. V. Semina, T. N. Semenets, I. A. Zamulaeva, E. I. Selivanova, Ya. V. Malyutina, Yu. A. Semin, V. I. Deigin, A. S. Saenko · Bulletin of Experimental Biology and Medicine. 140(3):348–351
Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.
- Population / setting
- Mice; splenic colony-forming, CD34-positive-cell and T-cell assays
- Source reviewed
- Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
- Mechanistic interpretation does not establish CD34 as a directly bound receptor.
- Related-isomer experiments do not prove clinical effects of either marketed preparation.
- Colony formation is not proof of long-term self-renewing stem-cell expansion.
Reviewed 2026-10-03.
Animal research · 2016
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
Study notes and original source
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Preparation-specific research; no equivalence inferred
Deigin V, Ksenofontova O, Khrushchev A, Yatskin O, Goryacheva A, Ivanov V. · ChemMedChem
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
- Population / setting
- Intact mice, donor marrow and irradiated recipient-mouse colony assays
- Source reviewed
- Full primary text checked: compound 3 is the alanine cyclic scaffold later discussed as AWE18 in the 2023 platform review. Experimental comparisons concern mice and irradiated marrow; supporting raw data not independently reanalyzed.
Study limitations
- AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2003
[Immunogenic peptide neogen stimulates postradiation recovery thrombopoiesis].
Neogen was investigated for platelet and bleeding-time recovery after irradiation in mice. Animal recovery endpoints do not establish clinical hematologic benefit.
Study notes and original source
[Immunogenic peptide neogen stimulates postradiation recovery thrombopoiesis].
Preparation-specific research; no equivalence inferred
Ziablitskiĭ VM, Semina OV, Semenets TN, Starosel'skaia AN, Romanovskaia VN, Mikhal'skaia TIu, Poverennyĭ AM, Deĭgin VI. · Radiatsionnaia biologiia, radioecologiia
Neogen was investigated for platelet and bleeding-time recovery after irradiation in mice. Animal recovery endpoints do not establish clinical hematologic benefit.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2024
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
Study notes and original source
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Defined synthetic peptide / analogue
Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova · International Journal of Molecular Sciences 25(24):13385
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
Results and tables
Reported findings and study design
Population or model Source-specific experimental population
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Intact-mouse spleen colony formation | Control 14.5±1.6 colonies per 100,000 cells; CP-88 injected 19.9±1.3, oral 19.3±1.3; both marked p<0.05 versus control. | |
| Stemokin in the same table | 14.7±0.7 injected and 14.3±1.8 oral; neither carries a significance mark. |
No CP-88-versus-Stemokin significance is established by separate control tests. Table 2 footnotes and Table 3 marker/header labels need clarification. Colony formation does not establish long-term stem-cell self-renewal or human benefit.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Source-specific experimental population
- Source reviewed
- Original full text retrieved from Europe PMC; experimental scope and interpretation checked. Supplementary methods and independent replication remain review targets.
Study limitations
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Reviewed 2026-11-06.
Review of earlier studies · 2023
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
Study notes and original source
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Defined synthetic peptide / analogue
Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
- Population / setting
- Source-specific experimental population
- Source reviewed
- Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Study limitations
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Reviewed 2026-10-02.
Comparison in people · 2015
Stemokin in treatment and prevention of pyoderma in military personnel
The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.
Study notes and original source
Stemokin in treatment and prevention of pyoderma in military personnel
Defined synthetic peptide / analogue · Conference abstract
V. V. Gladko, N. N. Kakhishvili, S. A. Masyukova · Conference abstract on Dermatology in Russia, posted 25 January 2015; underlying study dates unresolved
The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.
Results and tables
Reported findings and study design
Population or model Treatment comparison: 39 adjunctive Stemokin versus 37 basic care; prevention comparison: 40 versus 36. Participant overlap unresolved.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported clinical recovery in the adjunct-treatment arm | 74.36% among 39 treated participants | |
| Reported pyoderma incidence in the prevention arm | 17.5% among 40 participants over follow-up up to 12 months |
These arm-level proportions are not causal effect estimates. The excerpt gives no percentages for the comparison group. Allocation, blinding and overlap between the treatment and prevention groups remain unresolved; the reports may count some participants more than once.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- Treatment comparison: 39 adjunctive Stemokin versus 37 basic care; prevention comparison: 40 versus 36. Participant overlap unresolved.
- Source reviewed
- Indexed original abstract passages rechecked; direct host access returned 403. Reported active-arm recovery and prevention proportions recovered; full dissertation appraisal pending.
Study limitations
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Reviewed 2026-11-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗